Proteostasis and Elan in Discovery Pact

The alliance will combine Proteostasis’ discovery technology, novel targets and compounds that modulate key Proteostasis Network pathways with Elan’s strength in proprietary animal models, biology, medicinal chemistry and clinical development.

Proteostasis Therapeutics and Elan Corp. have established a strategic business relationship to advance Proteostasis’ platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders.

Such diseases could include Parkinson’s, Huntington’s, multiple sclerosis and amyotrophic lateral sclerosis (ALS), and a broad array of dementia-related diseases including Alzheimer’s.

The alliance will combine Proteostasis’ discovery technology, novel targets and compounds that modulate key Proteostasis Network pathways with Elan’s strength in proprietary animal models, biology, medicinal chemistry and clinical development.